Appendix 3B
September 30, 2019
Imagion Biosystems Limited has announced Appendix 3B, “New issue announcement, application for quotation of additional securities and agreement.” Read Appendix 3B.
Category: Investor updates
Imagion Commences Non Deal Roadshow in Australia
September 10, 2019
Imagion Biosystems Limited (ASX:IBX) (the Company), a Company dedicated to improving healthcare through the earlier detection of cancer, is pleased to share the updated investor
Imagion presents positive new data at World Molecular Imaging Congress
September 9, 2019
Imagion presents positive new data at World Molecular Imaging Congress Study reports MagSense® utility as a potential MRI contrast agent MELBOURNE — Imagion Biosystems Limited
Appendix 4D and Half-Year Report
August 31, 2019
The following Appendix 4D and Half-Year Report has been lodged with ASX. Read Appendix 4D and Half-Year Report.
Biotech Daily — Dr Boreham's Crucible: Imagion Biosystems
August 28, 2019
Tim Boreham profiles Imagion Biosystems in this 5-1/2 page article. Read the profile.
Imagion Biosystem's August Newsletter
August 23, 2019
In this issue: FDA “Breakthrough Device Designation” Tox Study Completion WMIC 2019 Poster Q&A with Bob Proulx Read the issue.
Imagion Biosystems Initiates Regulatory Communications for First-in-Human Study
August 6, 2019
Imagion Biosystems has filed a Pre-Submission with the U.S. Food and Drug Administration (FDA), the first step is gaining approval to commence its first-in-human study.
Imagion Biosystems receives A$2 million in R&D tax incentives
July 26, 2019
Imagion Biosystems Limited has received A$2 million in R&D tax incentives from the Australian Tax Office (ATO). In May 2019, the Company reported that it
Proactiveinvestors Interviews Bob Proulx on FDA Fast Track Status for MagSense® Imaging
July 26, 2019
Proactiveinvestors interviews Bob Proulx on what FDA’s designation of MagSense® imaging as a “breakthrough device” means for the company and its investors: https://youtu.be/X4HLKyIl6Zo
Imagion Biosystems Receives FDA Breakthrough Device Designation
July 18, 2019
Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, today announced that it has received